Novartis' biosimilar stacks up to Amgen's Neupogen in Phase III; Chinese biotech Adagene raises $8M;

@FierceBiotech: Merck splashes into antibiotics with $9.5B Cubist deal. Story | Follow @FierceBiotech

@JohnCFierce: Agios' AG-221 racks up more cancer remissions, setting the stage for a pivotal challenge. Article | Follow @JohnCFierce

@DamianFierce: Sun Pharma has a nuanced approach to Twitter. More | Follow @DamianFierce

> Novartis' ($NVS) biosimilar of Amgen's ($AMGN) Neupogen proved itself similarly safe and effective as its reference product in a Phase III trial, the company said. News

> Chinese biotech startup Adagene raised $8 million in Series A cash to advance its antibody discovery platform. Fidelity Biosciences, Fidelity Asia Growth and WuXi PharmaTech ($WX) participated in the round. More

Medical Device News

@FierceMedDev: Physicians weigh in on ventricular assist devices for treating heart failure. Story | Follow @FierceMedDev

@EmilyWFierce: AstraZeneca scores a victory in pay-for-delay Nexium case. Article | Follow @EmilyWFierce

> J&J gains FDA clearance for rare pediatric spinal device. More

> National Cancer Institute backs startup's hazardous drug containment device. Story

> BlackBerry, NantHealth to launch HIPAA secure smartphone genome browser. News

Pharma News

@FiercePharma: Top-read pharma news this weekend: With Pfizer on the loose, traders worry Actavis-Allergan M&A saga isn't over yet. Article | Follow @FiercePharma

@EricPFierce: ICYMI: Sanofi, Viehbacher accused of kickback scheme in whistleblower suit. More | Follow @EricPFierce

@CarlyHFierce: ICYMI: Long-acting Copaxone to launch early next year in Europe, Teva says. Story | Follow @CarlyHFierce

> Genentech's top-billing Lucentis users are also top-paid speakers: NYT. News

> European watchdogs pull Mylan, Abbott generics on contractor's data problems. Article

> Merck adds heft to hospital biz with $9.5B Cubist buyout. Report

CRO News

> WuXi moves to list a subsidiary on the Chinese market. More

> Recipharm cues job cuts as a long-time partner drops out. Report

> Catalent signs on to help Sellas get a repurposed drug to the finish line. Article

> INC Research lends its weight to trial site advocacy group. Item

> EU nations yank drugs over GVK data scandal. Story

Biotech IT News

> Hackers use Wall Street know-how to steal stock-moving biotech info. More

> Flatiron Health teams with Foundation Medicine to develop oncology platform. Report

> Ex-Pfizer SVP named CEO of BioClinica. Item

> Documents reveal FDA's use of computer forensics to uncover data falsification. Story

> 23andMe gets regulatory thumbs-up to sell DNA tests in U.K. Article

Animal Health News

> Kindred shares plummet as company nixes atopic dermatitis drug. Report

> Newly sequenced ferret genome reveals clues to human lung diseases. More

> Report: New FDA policy on animal antibiotics has loopholes. Item

> Eco Animal Health doubles pretax profit as it expands into North America. Story

> Nexvet partners with Virbac for ex-U.S. sales of canine osteoarthritis drug. Article

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.